IFITM1 Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application
| WB, IF, ICC, E |
---|---|
Primary Accession | P13164 |
Other Accession | NP_003632, 150010589 |
Reactivity | Human, Mouse, Rat |
Host | Rabbit |
Clonality | Polyclonal |
Isotype | IgG |
Calculated MW | Predicted: 14 kDa Observed: 14 kDa |
Application Notes | IFITM1 antibody can be used for detection of IFITM1 by Western blot at 1 - 2 µg/mL. Antibody can also be used for immunocytochemistry starting at 20 µg/mL. For immunofluorescence start at 20 µg/mL. |
Gene ID | 8519 |
---|---|
Target/Specificity | IFITM1; |
Reconstitution & Storage | IFITM1 antibody can be stored at 4℃ for three months and -20℃, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures. |
Precautions | IFITM1 Antibody is for research use only and not for use in diagnostic or therapeutic procedures. |
Name | IFITM1 (HGNC:5412) |
---|---|
Synonyms | CD225, IFI17 |
Function | IFN-induced antiviral protein which inhibits the entry of viruses to the host cell cytoplasm, permitting endocytosis, but preventing subsequent viral fusion and release of viral contents into the cytosol. Active against multiple viruses, including influenza A virus, SARS coronaviruses (SARS-CoV and SARS-CoV-2), Marburg virus (MARV), Ebola virus (EBOV), Dengue virus (DNV), West Nile virus (WNV), human immunodeficiency virus type 1 (HIV-1) and hepatitis C virus (HCV) (PubMed:26354436, PubMed:33270927). Can inhibit: influenza virus hemagglutinin protein-mediated viral entry, MARV and EBOV GP1,2- mediated viral entry and SARS-CoV and SARS-CoV-2 S protein-mediated viral entry. Also implicated in cell adhesion and control of cell growth and migration (PubMed:33270927). Inhibits SARS-CoV-2 S protein- mediated syncytia formation (PubMed:33051876). Plays a key role in the antiproliferative action of IFN-gamma either by inhibiting the ERK activation or by arresting cell growth in G1 phase in a p53-dependent manner. Acts as a positive regulator of osteoblast differentiation. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation (PubMed:26354436). IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome (PubMed:26354436). |
Cellular Location | Cell membrane; Single-pass membrane protein. Lysosome membrane |
Tissue Location | Bone (at protein level). Levels greatly elevated in colon cancer, cervical cancer, esophageal cancer and ovarian cancer Expressed in glioma cell lines. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
IFITM1 Antibody: IFITM1 (Interferon inducible transmembrane protein 1) is a member of the IFN-inducible transmembrane protein family. It is an essential mediator of interferon-gamma-induced antiproliferation and plays a role in the control of cell growth. IFITM1 is upregulated in several tumor types and may be useful as a tumor biomarker. Both mouse IFITM1 and IFITM3 are expressed on the cell surfaces of primordial germ cells in a developmentally-regulated manner. IFITM1 activity is required for primordial germ cell transit, and IFITM1 acts as a repulsive molecule by repelling non-IFITM1-expressing primordial germ cells from the mesoderm into the endoderm.
References
Deblandre GA, Marinx OP, Evans SS, et al. Expression cloning of an interferon-inducible 17 kDa membrane protein implicated in the control of cell growth. J. Biol. Chem. 1995; 270:23860-6.
Yang G, Xu Y, Chen X, et al. IFITM1 plays an essential role in the antiproliferative action of interferon-gamma. Oncogene. 2007; 26:594-603.
Akyerli CB, Beksac M, Holko M, et al. Expression of IFITM1 in chronic myeloid leukemia patients. Leuk. Res. 2005; 29:283-6.
Tanaka SS, Yamaguchi YL, Tsoi B, et al. IFITM/Mil/Fragilis family proteins IFITM1 and IFITM3 play distinct roles in mouse primordial germ cell homing and repulsion. Cell 2005; 9:745-6.
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.